Stockreport

CorMedix: A Shrinking Core And No Proven Second Engine [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF FY26 guidance of ~$310M (midpoint) masks underlying deceleration, as DefenCath declines from $258.8M in FY25 to $150M–$170M in FY26, with the year-end run rate likely m [Read more]